Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Que Dallara Takes Over Medtronic Diabetes At A Critical Moment

Executive Summary

Dallara is joining Medtronic from Honeywell, where she served as CEO of the conglomerate’s Connected Enterprise. The company also promoted Mike Marinaro to the president of Medtronic’s surgical robotics unit and Kweli Thomson to lead the cardiac rhythm management unit.

You may also be interested in...



JPM 2024 Roundup: Abbott And Medtronic Push Diabetes Tech, Edwards Updates Tricuspid Progress, Shockwave Bets On R&D

Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.

Faulty Defibrillator Claims Against Medtronic Dismissed

The plaintiff says he was hurt by a Medtronic defibrillator and related components, but the US Fifth Circuit found his claims were either preempted or weren’t backed by the evidence.

JPM 2022: Dexcom, Edwards, J&J, Medtronic, ResMed

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the first day of the meeting.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel